Stepanovskoye, Russian Federation

The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

Boston Aging Together Study

Study schedule: -There is a one-time study visit. It will take about two hours. The interviewer will come to you. Study activities may include: -Having an interview with a researcher. Treatment or experiment details: -The study is interested in learning about your experiences in an open-ended way. -The interview will be about your relationship with your parent with dementia. -The interview is completely confidential. -There is no treatment or experiment being tested. Additional details: -Participants will receive $40 for completing the study.

Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET

MGCD265 is an orally administered receptor tyrosine kinase inhibitor that targets MET and other receptors. This study is a Phase 2 trial of MGCD265 in patients with locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) that has activating genetic changes of the MET gene (mutation or amplification [increase number of gene copies]). Testing for tumor gene changes can be performed in tumor tissue or blood samples. Patients must have previously received treatment with chemotherapy. The number of patients to be enrolled will depend on how many enrolled patients experience tumor size reduction. MGCD265 will be administered orally, twice daily. The study is designed to evaluate whether the number of patients experiencing tumor size reduction is substantially higher than would be expected with other available treatments

A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

* Phase 1/1b to establish the maximum tolerated dose of the combination of study drugs in patients with advanced solid tumor malignancies with a KRAS G12C mutation. * Phase 2 to evaluate clinical activity of the combination of study drugs in selected solid tumor malignancies with KRAS G12C mutation.

A Phase 2, Single-Arm, Open-Label Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy by Immune Effector Cell Therapy

For more information, please contact Incyte Corporation at 1.855.463.3463

A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (KRYSTAL-10)

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

The purpose of this study is to provide continued use of parsaclisib as monotherapy or in combination with itacitinib, ruxolitinib, or ibrutinib to participants who are currently enrolled in an Incyte-sponsored study and receiving the same treatment, who have at least stable disease, who are obtaining clinical benefit (in the opinion of the investigator) on the current study treatment, as defined by the parent Protocol, and who are unable to access parsaclisib as monotherapy or in combination with itacitinib, ruxolitinib, or ibrutinib outside a clinical study. Participants will continue on the same dose and schedule as the ones being administered in the Incyte- sponsored parent Protocol at the time of the rollover. The study will collect and assess safety information with regards to AEs.

Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation (OPTIMAL)

The goal of the OPTIMAL study is to gradually reduce anti-rejection medication(s) in liver transplant recipients over a period of time until the medication(s) are stopped. This is called immunosuppression withdrawal. As part of the OPTIMAL study, investigators will also do blood and liver biopsy tests to see whether they can identify common markers of immune systems that are able to tolerate transplanted livers without immunosuppressive medications. Identification of these markers and tests will help transplant doctors predict whether it is safe to decrease or stop anti-rejection medication(s) for future liver transplant recipients. In general, study visits will consist of a brief physical exam, and some visits will also include questionnaires as well as blood, urine, stool (fecal), and liver biopsy collections. In total, participation may last between 3.5 and 6 years. For more information, visit [ www.optimalstudy.org ](http://www.optimalstudy.org) For more information, visit [www.optimalstudy.org](https://www.optimalstudy.org)

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

* Phase 1 dose escalation of MRTX849 to determine maximum tolerated dose. * Phase 1b expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 to recommend Phase 2 regimens. * Separate Phase 2 cohorts of patients stratified by histological diagnosis for evaluation of clinical activity of MRTX849. * MRTX849 will be administered orally in a continuous regimen. The **Pilot Phase 1b Combination with Pembrolizumab** arm of the study will evaluate the safety, tolerability, PK, and clinical activity of the investigational study agent, MRTX849, in combination with pembrolizumab in patients with NSCLC. The **Pilot Phase 1b Combination with Cetuximab** arm of the study will evaluate the safety, tolerability, PK, and clinical activity of MRTX849 in combination with cetuximab in patients with CRC. Lastly, the **Pilot Phase 1b Combination with Afatinib** arm of the study will evaluate the safety, tolerability, PK and clinical activity of MRTX849 in combination with afatinib in patients with NSCLC.

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma